GLAUKOS Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Glaukos (GKOS) officer Tomas Navratil filed a notice to sell 13,744 shares, valued at $2.48 million, under Rule 144. This follows prior sales of 1,537 and 716 shares in June and July 2026, respectively.
Glaukos (GKOS) shares rose 8% since its last earnings report, beating estimates with Q2 revenue of $185.6M (up 50% YoY) and narrowed losses. Growth was driven by iDose TR adoption and expanded guidance to $680M-$700M for 2026. The company has no debt and $286.2M in cash. Analysts have raised estimates, with a Zacks Rank #3 (Hold).
Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.
Over the past 7 days, alphai's AI scored 3 news stories mentioning GKOS (GLAUKOS Corp). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent GKOS coverage spans earnings, insider activity and financial news.
In the last 30 days, GKOS insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($15.0M). The most active reporter was Gilliam Joseph E, PRESIDENT & COO, with 2 filings. 20% of those filings were made under pre-arranged Rule 10b5-1 plans.
The pending insider sale could add short‑term selling pressure if executed, but the amount is modest relative to float.
Guidance raise may support short‑term upside, but the article is a recap with no new catalyst.
Strong earnings beat and upgraded guidance suggest near‑term upside.
A modest insider sale by a director may signal limited confidence, but the amount is small relative to market cap.
Strong earnings beat and raised guidance likely support further price appreciation.
alphai scores every news story that mentions GKOS with an AI model for sentiment and relevance, and aggregates insider trades from GLAUKOS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Glaukos (GKOS) officer Tomas Navratil filed a notice to sell 13,744 shares, valued at $2.48 million, under Rule 144. This follows prior sales of 1,537 and 716 shares in June and July 2026, respectively.
1 min readGlaukos (GKOS) shares rose 8% since its last earnings report, beating estimates with Q2 revenue of $185.6M (up 50% YoY) and narrowed losses. Growth was driven by iDose TR adoption and expanded guidance to $680M-$700M for 2026. The company has no debt and $286.2M in cash. Analysts have raised estimates, with a Zacks Rank #3 (Hold).
3 min readGlaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.
2 min readKliman Gilbert H sold 2,500 shares of GLAUKOS Corp (GKOS) at $190.00 ($0.48M total) on 2026-08-19.
1 min readGlaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.
2 min readGlaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.
2 min readGilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.
2 min readThurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 20,000 shares of GLAUKOS Corp (GKOS) at $180.13 ($3.60M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
1 min readSimply Wall St reports Glaukos (GKOS) posted record Q2 net sales, citing iDose TR and the Epioxa launch, and raised full-year 2026 net sales guidance. The stock closed at $180.02, up 17.69% over 30 days and 62.59% YTD. The article contrasts a $165 fair value narrative with an SWS DCF cash flow value of $380.09.
6 min readGlaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.
7 min read
